TDT-3

TDT-3 is an experimental T-cell receptor (TCR) engineered T-cell therapy developed by Oslo University Hospital for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The therapy utilizes autologous T cells modified to express a specific TCR that recognizes a peptide fragment of terminal deoxynucleotidyl transferase (TdT) presented by the HLA-A*02:01 molecule. TdT is an intracellular enzyme primarily expressed in the nucleus of malignant lymphoblasts in the vast majority of B-cell and T-cell ALL cases, but it is absent in mature lymphocytes and most healthy tissues, including hematopoietic stem cells. This expression profile allows TDT-3 to selectively target and eliminate leukemic cells while preserving the broader immune system and avoiding the severe myeloablation often associated with other pan-lymphocyte targets like CD19 or CD7. TDT-3 is currently being evaluated in Phase 1 clinical trials to assess its safety and preliminary efficacy in patients with TdT-positive hematological malignancies.

Other names

TdT-specific TCR-engineered T cellsT-cell receptor engineered T cells targeting Terminal Deoxynucleotidyl Transferase